ABL1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (5 open) [3].

ATR is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

ATRX is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BAP1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BAP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BARD1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

BLM is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BLM status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and urothelial carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].

BRCA1 is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

BRCA2 is an inclusion eligibility criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

BRD4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRIP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

CHEK1 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CREBBP status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DOT1L is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DOT1L status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain EGFR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [3].

EP300 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EP300 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 9 clinical trials for urothelial carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open) [3].

ERBB3 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCA status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FANCB is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCB status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FANCC is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCC status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

FANCD2 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCD2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FANCE is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCE status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

FANCF is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCF status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FANCG is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCG status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

FANCI is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCI status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FANCL is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCL status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

FANCM is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCM status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FGF1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF10 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF14 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF19 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF19 status and urothelial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF23 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF3 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF4 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

FGF5 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF6 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGF9 status and urothelial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 13 clinical trials for urothelial carcinoma, of which 11 are open and 2 are closed. Of the trials that contain FGFR1 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 6 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), and 1 is phase 3 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 11 clinical trials for urothelial carcinoma, of which 10 are open and 1 is closed. Of the trials that contain FGFR2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 16 clinical trials for urothelial carcinoma, of which 13 are open and 3 are closed. Of the trials that contain FGFR3 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [3].

Erdafitinib has evidence of efficacy in patients with FGFR3 mutation in urothelial carcinoma [3].

FGFR4 is an inclusion eligibility criterion in 7 clinical trials for urothelial carcinoma, of which 6 are open and 1 is closed. Of the trials that contain FGFR4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IKBKE is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IKBKE status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MCPH1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MDC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MEN1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MEN1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MRE11A status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

MSH2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH2 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NBN is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NBN status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PALB2 is an inclusion eligibility criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PALB2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS2 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

POLQ is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLQ status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

RAD51 is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

RAD51B is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

RAD51D is an inclusion eligibility criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51D status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

RAD52 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD52 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RBBP8 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RBBP8 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RECQL4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RECQL4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SLX4 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STK11 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STK11 status and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

Erdafitinib has evidence of efficacy in patients with TACC3 mutation in urothelial carcinoma [3].

TEK is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WRN is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WRN status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC2 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC3 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC4 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC5 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC5 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC6 is an inclusion eligibility criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC6 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].